JP2024026125A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2024026125A5 JP2024026125A5 JP2023197046A JP2023197046A JP2024026125A5 JP 2024026125 A5 JP2024026125 A5 JP 2024026125A5 JP 2023197046 A JP2023197046 A JP 2023197046A JP 2023197046 A JP2023197046 A JP 2023197046A JP 2024026125 A5 JP2024026125 A5 JP 2024026125A5
- Authority
- JP
- Japan
- Prior art keywords
- cells
- mouse
- human
- cell
- promoter
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025130460A JP2025163187A (ja) | 2017-06-12 | 2025-08-05 | 全身免疫抑制を必要としない同種免疫寛容 |
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762518151P | 2017-06-12 | 2017-06-12 | |
| US62/518,151 | 2017-06-12 | ||
| US201862666626P | 2018-05-03 | 2018-05-03 | |
| US62/666,626 | 2018-05-03 | ||
| JP2020518110A JP7391016B2 (ja) | 2017-06-12 | 2018-06-12 | 全身免疫抑制を必要としない同種免疫寛容 |
| PCT/CA2018/050706 WO2018227286A1 (en) | 2017-06-12 | 2018-06-12 | Allograft tolerance without the need for systemic immune suppression |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020518110A Division JP7391016B2 (ja) | 2017-06-12 | 2018-06-12 | 全身免疫抑制を必要としない同種免疫寛容 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025130460A Division JP2025163187A (ja) | 2017-06-12 | 2025-08-05 | 全身免疫抑制を必要としない同種免疫寛容 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024026125A JP2024026125A (ja) | 2024-02-28 |
| JP2024026125A5 true JP2024026125A5 (enExample) | 2024-05-17 |
| JP7724834B2 JP7724834B2 (ja) | 2025-08-18 |
Family
ID=64658770
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020518110A Active JP7391016B2 (ja) | 2017-06-12 | 2018-06-12 | 全身免疫抑制を必要としない同種免疫寛容 |
| JP2023197046A Active JP7724834B2 (ja) | 2017-06-12 | 2023-11-21 | 全身免疫抑制を必要としない同種免疫寛容 |
| JP2025130460A Pending JP2025163187A (ja) | 2017-06-12 | 2025-08-05 | 全身免疫抑制を必要としない同種免疫寛容 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020518110A Active JP7391016B2 (ja) | 2017-06-12 | 2018-06-12 | 全身免疫抑制を必要としない同種免疫寛容 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025130460A Pending JP2025163187A (ja) | 2017-06-12 | 2025-08-05 | 全身免疫抑制を必要としない同種免疫寛容 |
Country Status (10)
| Country | Link |
|---|---|
| US (3) | US20210161971A1 (enExample) |
| EP (1) | EP3638258A4 (enExample) |
| JP (3) | JP7391016B2 (enExample) |
| KR (2) | KR102738427B1 (enExample) |
| CN (2) | CN120041380A (enExample) |
| AU (3) | AU2018285972B2 (enExample) |
| CA (1) | CA3064297A1 (enExample) |
| GB (1) | GB2588249B (enExample) |
| IL (2) | IL270835B2 (enExample) |
| WO (1) | WO2018227286A1 (enExample) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10704021B2 (en) | 2012-03-15 | 2020-07-07 | Flodesign Sonics, Inc. | Acoustic perfusion devices |
| WO2015105955A1 (en) | 2014-01-08 | 2015-07-16 | Flodesign Sonics, Inc. | Acoustophoresis device with dual acoustophoretic chamber |
| US11377651B2 (en) | 2016-10-19 | 2022-07-05 | Flodesign Sonics, Inc. | Cell therapy processes utilizing acoustophoresis |
| US11708572B2 (en) | 2015-04-29 | 2023-07-25 | Flodesign Sonics, Inc. | Acoustic cell separation techniques and processes |
| JP2018515139A (ja) | 2015-05-08 | 2018-06-14 | プレジデント アンド フェローズ オブ ハーバード カレッジ | 万能ドナー幹細胞および関連する方法 |
| BR112020009889A2 (pt) | 2017-12-14 | 2020-11-03 | Flodesign Sonics, Inc. | acionador e controlador de transdutor acústico |
| KR102592176B1 (ko) | 2018-01-05 | 2023-10-20 | 플레이틀렛 바이오제네시스, 인크. | 거핵구 생성을 위한 조성물 및 방법 |
| WO2020006539A1 (en) | 2018-06-29 | 2020-01-02 | Platelet Biogenesis, Inc. | Compositions for drug delivery and methods of use thereof |
| US12378572B2 (en) | 2018-09-07 | 2025-08-05 | Crispr Therapeutics Ag | Universal donor cells |
| US20220016181A1 (en) * | 2018-12-13 | 2022-01-20 | Sinai Health System | Immunomodulatory cells and uses thereof |
| AU2020228979B2 (en) * | 2019-02-27 | 2025-05-29 | Takeda Pharmaceutical Company Limited | Improved stem cell populations for allogeneic therapy |
| CN110179824A (zh) * | 2019-04-01 | 2019-08-30 | 普米斯生物技术(珠海)有限公司 | 一种通过免疫调控治疗ii型糖尿病的新方法 |
| US11162079B2 (en) | 2019-05-10 | 2021-11-02 | The Regents Of The University Of California | Blood type O Rh-hypo-immunogenic pluripotent cells |
| JP2022532174A (ja) | 2019-05-10 | 2022-07-13 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 修飾多能性細胞 |
| US20220307013A1 (en) * | 2019-08-30 | 2022-09-29 | The Regents Of The University Of California | Gene fragment overexpression screening methodologies, and uses thereof |
| WO2021044377A1 (en) | 2019-09-05 | 2021-03-11 | Crispr Therapeutics Ag | Universal donor cells |
| EP4090743A1 (en) | 2020-01-13 | 2022-11-23 | Sana Biotechnology, Inc. | Modification of blood type antigens |
| US20230149428A1 (en) * | 2020-02-14 | 2023-05-18 | Asklepios Biopharmaceutical, Inc. | Method of treating gene therapy associated toxicity with antibiotics |
| CN115335087A (zh) * | 2020-04-01 | 2022-11-11 | 南京传奇生物科技有限公司 | 用于减少同种异体细胞疗法中的移植物排斥的组合物和方法 |
| JP2023523806A (ja) * | 2020-04-30 | 2023-06-07 | リサーチ インスティテュート アット ネイションワイド チルドレンズ ホスピタル | ＴＧＦ－β耐性ＮＫ細胞での免疫抑制の克服 |
| EP4196568A1 (en) * | 2020-08-13 | 2023-06-21 | Sana Biotechnology, Inc. | Methods of treating sensitized patients with hypoimmunogenic cells, and associated methods and compositions |
| CN112089847B (zh) * | 2020-08-31 | 2021-05-28 | 高连如 | 一种融合pnv靶向缺血心肌血管的干细胞药物及制备方法 |
| US11459372B2 (en) | 2020-11-30 | 2022-10-04 | Crispr Therapeutics Ag | Gene-edited natural killer cells |
| WO2022144632A1 (en) | 2020-12-30 | 2022-07-07 | Crispr Therapeutics Ag | Compositions and methods for differentiating stem cells into nk cells |
| WO2022144856A1 (en) | 2020-12-31 | 2022-07-07 | Crispr Therapeutics Ag | Universal donor cells |
| CN112972681B (zh) * | 2021-01-27 | 2022-06-07 | 西安交通大学 | Mt-nd6作为新靶点在代谢综合征诊断和治疗药物中的应用 |
| CN115124625B (zh) * | 2021-03-24 | 2024-11-26 | 圣安生医股份有限公司 | 免疫调节及抗肿瘤相关纳米抗体、其核酸编码序列及应用 |
| WO2022269393A1 (en) * | 2021-06-23 | 2022-12-29 | Crispr Therapeutics Ag | Engineered cells with improved protection from natural killer cell killing |
| WO2023023278A2 (en) * | 2021-08-18 | 2023-02-23 | University Of Utah Research Foundation | Multigene constructs for treatment of age-related macular degeneration and other complement dysregulation-related conditions |
| CN115873902A (zh) * | 2021-11-30 | 2023-03-31 | 百奥赛图(北京)医药科技股份有限公司 | 一种cd200和/或cd200r基因人源化的非人动物及其构建方法和应用 |
| KR102803344B1 (ko) * | 2022-01-19 | 2025-05-07 | 고려대학교 산학협력단 | Mfg-e8의 활성 제어를 통한 전능성 줄기세포의 선택적 세포사멸 유도 |
| CN117384851B (zh) * | 2022-07-11 | 2025-11-21 | 士泽生物医药（苏州）有限公司 | 一种表达faslg的通用型细胞及其制备方法 |
| WO2024091959A1 (en) * | 2022-10-24 | 2024-05-02 | The Regents Of The University Of California | Drug resistant immune cells |
| CN116785312B (zh) * | 2023-06-21 | 2023-11-14 | 天津医科大学眼科医院 | miR-15a-5p在治疗眼底疾病中的应用 |
| CN119055769B (zh) * | 2023-08-17 | 2025-09-05 | 南方医科大学南方医院 | 抗血管生成药物在提高软组织移植物保留率中的应用 |
| WO2025064604A2 (en) * | 2023-09-19 | 2025-03-27 | Musc Foundation For Research Development | Combination engineered cell therapy |
| WO2025106557A1 (en) * | 2023-11-13 | 2025-05-22 | Bluerock Therapeutics Lp | Genetically modified cells for enhanced immune evasion in allogeneic cellular therapies |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2002250333A1 (en) * | 2001-03-13 | 2002-09-24 | Johns Hopkins University School Of Medicine | Fas ligand-expressing hematopoietic cells for transplantation |
| EP1879448A2 (en) * | 2005-02-25 | 2008-01-23 | University of Chicago | Compositions and methods related to serpin spi6 |
| EP1957633B1 (en) * | 2005-10-13 | 2013-12-18 | Anthrogenesis Corporation | Immunomodulation using placental stem cells |
| EP2300023A2 (en) | 2008-05-16 | 2011-03-30 | Genelux Corporation | Microorganisms for preventing and treating neoplasms accompanying cellular therapy |
| US8592364B2 (en) * | 2010-02-11 | 2013-11-26 | Ecole Polytechnique Federale de Lausanne (“EPFL”) | CCR7 ligand delivery and co-delivery in immunotherapy |
| FI3421486T3 (fi) * | 2012-06-22 | 2023-12-15 | Dartmouth College | Uusia vista-ig-rakenteita ja vista-ig:n käyttö autoimmuuni-, allergia- ja tulehdushäiriöiden hoitamiseksi |
| SG11201500799YA (en) * | 2012-07-31 | 2015-03-30 | Basil M Hantash | Hla g-modified cells and methods |
| WO2015009948A1 (en) * | 2013-07-19 | 2015-01-22 | Regents Of The University Of California | Milk fat globule epidermal growth factor 8 regulates fatty acid uptake |
| EP3480213B1 (en) | 2014-06-18 | 2019-11-13 | Albert Einstein College of Medicine | Syntac polypeptides and uses thereof |
| WO2016081924A1 (en) * | 2014-11-20 | 2016-05-26 | Duke University | Compositions, systems and methods for cell therapy |
| SMT201900178T1 (it) | 2014-12-05 | 2019-05-10 | Regeneron Pharma | Animali diversi dall’uomo aventi un gruppo umanizzato del gene 47 di differenziazione |
| US20180044686A1 (en) | 2015-03-09 | 2018-02-15 | Sinai Health System | Tools and methods for using cell division loci to control proliferation of cells |
| AU2016243128A1 (en) * | 2015-03-27 | 2017-11-02 | University Of Southern California | HLA-G as a novel target for CAR T-cell immunotherapy |
| JP2018515139A (ja) | 2015-05-08 | 2018-06-14 | プレジデント アンド フェローズ オブ ハーバード カレッジ | 万能ドナー幹細胞および関連する方法 |
| EP3362074B1 (en) * | 2015-10-16 | 2023-08-09 | President and Fellows of Harvard College | Regulatory t cell pd-1 modulation for regulating t cell effector immune responses |
| EA201991692A1 (ru) | 2017-01-13 | 2019-12-30 | Дзе Риджентс Оф Дзе Юниверсити Оф Калифорния | Иммуносконструированные плюрипотентные клетки |
| EP4017508A1 (en) | 2019-08-23 | 2022-06-29 | Sana Biotechnology, Inc. | Cd24 expressing cells and uses thereof |
-
2018
- 2018-06-12 GB GB1917408.5A patent/GB2588249B/en active Active
- 2018-06-12 JP JP2020518110A patent/JP7391016B2/ja active Active
- 2018-06-12 CA CA3064297A patent/CA3064297A1/en active Pending
- 2018-06-12 CN CN202510144417.3A patent/CN120041380A/zh active Pending
- 2018-06-12 EP EP18818206.7A patent/EP3638258A4/en active Pending
- 2018-06-12 AU AU2018285972A patent/AU2018285972B2/en active Active
- 2018-06-12 KR KR1020207000550A patent/KR102738427B1/ko active Active
- 2018-06-12 WO PCT/CA2018/050706 patent/WO2018227286A1/en not_active Ceased
- 2018-06-12 CN CN201880038734.5A patent/CN110869494B/zh active Active
- 2018-06-12 KR KR1020247039926A patent/KR20250005439A/ko active Pending
- 2018-06-12 US US16/621,490 patent/US20210161971A1/en not_active Abandoned
- 2018-06-12 IL IL270835A patent/IL270835B2/en unknown
- 2018-06-12 IL IL314638A patent/IL314638A/en unknown
-
2023
- 2023-02-27 US US18/175,409 patent/US12178835B2/en active Active
- 2023-06-15 AU AU2023203759A patent/AU2023203759B2/en active Active
- 2023-11-21 JP JP2023197046A patent/JP7724834B2/ja active Active
-
2024
- 2024-11-15 US US18/949,799 patent/US20250144154A1/en active Pending
-
2025
- 2025-08-05 JP JP2025130460A patent/JP2025163187A/ja active Pending
- 2025-08-18 AU AU2025217410A patent/AU2025217410A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024026125A5 (enExample) | ||
| JP2020523037A5 (enExample) | ||
| GB2588249A (en) | Allograft tolerance without the need for systemic immune suppression | |
| KR102794868B1 (ko) | 범용 공여자 세포 | |
| AU666142B2 (en) | Viral recombinant vectors for expression in muscle cells | |
| JP4280708B2 (ja) | 虚血性心筋症において幹細胞のホーミングおよび組織再生を仲介するストローマ細胞由来因子−１（ｓｄｆ−１） | |
| IL308706A (en) | Compositions and methods for the treatment of hemoglobinopathies | |
| US20190184035A1 (en) | Bcl11a homing endonuclease variants, compositions, and methods of use | |
| US20020151680A1 (en) | Materials and methods involving hybrid vascular endothelial growth factor DNAs and proteins | |
| US6177272B1 (en) | Method for treating vascular proliferative diseases with p27 and fusions thereof | |
| JP7693555B2 (ja) | タンパク質分子とその用途 | |
| JP2004507208A5 (enExample) | ||
| JP2006509043A (ja) | 細胞に基づくｖｅｇｆ送達 | |
| US12385070B2 (en) | Homology directed repair compositions for the treatment of hemoglobinopathies | |
| US20060177932A1 (en) | Expansion agents for stem cells | |
| JPH1189587A (ja) | 遺伝的に改変された細胞および疾患の予防または治療におけるそれらの使用 | |
| JP2025038075A (ja) | 造血細胞の遺伝子改変のための方法 | |
| JPH11503011A (ja) | 条件発現系 | |
| TW202214279A (zh) | 溶瘤病毒與經改造的免疫細胞聯合治療腫瘤 | |
| JP2025516681A (ja) | 血液適合性を有する血管内移植用細胞、この製造方法および用途 | |
| CN111356463A (zh) | 使用多能干细胞的自杀基因脑肿瘤治疗药 | |
| JP2021098717A (ja) | 新規の再生治療剤としてのｃａｍｋｋ１ | |
| Staquicini et al. | Phage display technology for stem cell delivery and systemic therapy | |
| KR100765496B1 (ko) | 히레귤린 베타1의 ｅｇｆ-성 도메인 펩타이드를 암호화하는ｄｎａ 서열을 포함하는 재조합 아데노바이러스 및 이를포함하는 신경세포 분화 및 재생용 약학 조성물 | |
| US20030148952A1 (en) | Methods and materials for the recruitment of endothelial cells |